Cite
HARVARD Citation
Luigetti, M. et al. (2022). Real‐life experience with inotersen in hereditary transthyretin amyloidosis with late‐onset phenotype: Data from an early‐access program in Italy. European journal of neurology. pp. 2148-2155. [Online].